- Home
- CCBG vs KROS Comparison
CCBG vs KROS Comparison
Compare CCBG & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- KROS
- Stock Information
- Founded
- CCBG 1895
- KROS 2015
- Country
- CCBG United States
- KROS United States
- Employees
- CCBG N/A
- KROS N/A
- Industry
- CCBG Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CCBG Finance
- KROS Health Care
- Exchange
- CCBG Nasdaq
- KROS Nasdaq
- Market Cap
- CCBG 733.2M
- KROS 565.0M
- IPO Year
- CCBG N/A
- KROS 2020
- Fundamental
- Price
- CCBG $43.74
- KROS $16.04
- Analyst Decision
- CCBG Buy
- KROS Buy
- Analyst Count
- CCBG 1
- KROS 14
- Target Price
- CCBG $45.00
- KROS $20.56
- AVG Volume (30 Days)
- CCBG 36.2K
- KROS 383.7K
- Earning Date
- CCBG 10-21-2025
- KROS 11-05-2025
- Dividend Yield
- CCBG 2.17%
- KROS N/A
- EPS Growth
- CCBG 14.00
- KROS N/A
- EPS
- CCBG 3.42
- KROS 0.47
- Revenue
- CCBG $240,944,000.00
- KROS $232,844,000.00
- Revenue This Year
- CCBG $11.91
- KROS $5,998.31
- Revenue Next Year
- CCBG $3.57
- KROS N/A
- P/E Ratio
- CCBG $12.95
- KROS $34.39
- Revenue Growth
- CCBG 8.96
- KROS 85820.30
- 52 Week Low
- CCBG $32.38
- KROS $9.12
- 52 Week High
- CCBG $44.69
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CCBG 59.24
- KROS 62.64
- Support Level
- CCBG $42.52
- KROS $15.34
- Resistance Level
- CCBG $43.81
- KROS $16.11
- Average True Range (ATR)
- CCBG 0.82
- KROS 0.44
- MACD
- CCBG -0.10
- KROS -0.01
- Stochastic Oscillator
- CCBG 56.22
- KROS 94.25
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.